| Abstract: | The inflammatory response plays important roles in acne vulgaris and pain pathogenesis. In previous study, Esc‐1GN with anti‐inflammatory, antimicrobial, and lipopolysacchride (LPS) binding activity was identified from the skin of the frog Hylarana guentheri. Here, we report its therapeutic potentials for acne vulgaris and inflammatory pain. Esc‐1GN destroyed the cell membrane of Propionibacteria acnes in the membrane permeability assays. In addition, bacterial agglutination test suggested that Esc‐1GN triggered the agglutination of P. acnes, which was affected by LPS and Ca2+. Meanwhile, in vivo anti‐P. acnes and anti‐inflammatory effects of Esc‐1GN were confirmed by reducing the counts of P. acnes in mice ear, relieving P. acnes‐induced mice ear swelling, decreasing mRNA expression and the production of pro‐inflammatory cytokines, and attenuating the infiltration of inflammatory cells. Moreover, Esc‐1GN also displayed antinociceptive effect in mice induced by acetic acid and formalin. Therefore, Esc‐1GN is a promising candidate drug for treatment of acne vulgaris and inflammatory pain. |
